蛋白质组签名作为动脉样硬化负担的生物标志物
Lanyue Zhang1, Murad Omarov1, LingLing Xu1
1Institute for Stroke and Dementia Research (ISD), LMU University Hospital, LMU Munich, Munich, Germany.
Research square
|June 30, 2025
概括
新的血蛋白质组签名可以识别动脉样硬化负担并预测心血管事件. 这些基于血液的生物标志物为早期疾病检测和预防提供了可扩展的成像替代方案.
科学领域:
- 心血管研究研究心血管研究
- 蛋白质组学是指蛋白质组学.
- 生物标志物发现发现
背景情况:
- 动脉样硬化是一种沉默的,渐进的疾病,往往是晚诊断.
- 目前的方法缺乏可靠的循环生物标志物来量化动脉样硬化负担.
- 图像技术是有效的,但可能不是普遍可用的.
研究的目的:
- 定义反映动脉样硬化系统负担的血蛋白质组签名.
- 评估这些特征对未来心血管事件的预测能力.
- 探索蛋白质组学作为可扩展的成像替代方案,用于亚临床动脉样硬化检测.
主要方法:
- 机器学习 (CatBoost) 应用于来自44788名英国生物库参与者的血蛋白质 (Olink Explore 3072).
- 衍生出四种不同的蛋白质组签名 (整个蛋白质组,遗传,机械,动脉).
- 在外部队列 (KORA S4,KORA-Age1) 中验证了签名,并评估了主要不良心血管事件的预测.
主要成果:
- 四个蛋白质组签名强有力的歧视已知动脉样硬化 (ROC-AUC高达0.92) 个体.
- 签名预测了无症状个体未来的主要不良心血管事件 (HR/SD增加:1.70),改善了风险预测超出SCORE2.
- 签名水平与疾病负担相关,并在验证队列中预测了心肌梗塞和中风.
结论:
- 蛋白质组特征有效捕捉动脉样硬化负担,并提高无症状个体的心血管风险预测.
- 血蛋白质组学为识别亚临床动脉样硬化提供了一个可扩展和可访问的工具.
- 这些发现支持在心血管疾病预防策略中使用蛋白质组签名.
更多相关视频
10:03Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
5.4K
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
7.9K
相关概念视频
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
222
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
222
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
352
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
352
01:33Proteomics
8.0K
A proteome is the entire set of proteins that a cell type produces. We can study proteomes using the knowledge of genomes because genes code for mRNAs, and the mRNAs encode proteins. Although mRNA analysis is a step in the right direction, not all mRNAs are translated into proteins.
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term...
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term...
8.0K
01:27Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
41
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
41
01:30Atherosclerosis I: Introduction
93
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
93
01:26Atherosclerosis III: Management
41
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
41